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Summary We recently reported that six 1,4-dihydropyridine derivatives out of 57 screened effectively over-
came vincristine (VCR)-resistance in VCR-resistant (P388/VCR) leukaemia-bearing mice when the dihyd-
ropyridines and VCR were administered intraperitoneally (i.p.). Furthermore, among the six dihydropyridine
derivatives, two compounds, NK-250 and NK-252, most effectively overcame VCR-resistance while exhibiting
relatively low calcium antagonistic activity and toxicity. In this study, we examined whether NK-250 and
NK-252 could potentiate the antitumour activities of etoposide in mice with drug-sensitive (P388/S) or
VCR-resistant (P388/VCR) leukaemia cells when the anticancer agents and tumour cells were administered by
various routes. In both groups of mice inoculated i.p. with P388/S- and P388/VCR-leukaemia cells, the oral
(p.o.) administration of NK-250 combined with i.p. or intravenously (i.v.) administration of etoposide
(ip-po-ip trials and ip-po-iv trials) dramatically potentiated the antitumour activity of etoposide. Although
etoposide alone was less effective in treating mice inoculated i.v. with P388/S- and P388/VCR-leukaemia cells,
p.o. administration of NK-250 combined with i.p. or i.v. administration of etoposide (iv-po-ip trials and
iv-po-iv trials) potentiated the antitumour activity of etoposide to similar levels as in treating mice inoculated
i.p. with leukaemia cells. These 1,4-dihydropyridines were therefore highly effective in potentiating anticancer
drugs against both drug-sensitive and drug-resistant tumours.
Drug resistance, both intrinsic and acquired, remains a major
clinical obstacle in chemotherapy of tumours in man. Acquis-
ition of resistance to multiple anticancer agents such as Vinca
alkaloids, anthracyclines and epipodophyllotoxins is often
correlated with enhanced expression of gpl70, a membranous
glycoprotein with molecular weight of 170,000 coded by the
mdr-l gene: gpl70 catalyses the outward efflux of drugs,
resulting in reduced cellular accumulation of the chemothera-
peutic agents (Pastan & Gottesman, 1987; Beck, 1987; Brad-
ley et al., 1988). Gpl70 or its structural mdr-l gene has been
detected in tumour cells from patients with ovarian cancer,
soft tissue sarcoma, acute leukaemia, multiple myeloma, non-
Hodgkin's lymphoma, and several other human tumours
(Bell et al., 1985; Gerlach et al., 1987; Ma et al., 1987; Fojo
et al., 1987; Dalton et al., 1989; Nakagawara et al., 1990).
Goldstein et al. (1989) investigated the mdr-J mRNA levels in
many types of human cancers, and proposed that the expres-
sion of mdr-J was associated with several intrinsically resis-
tant cancers. They also observed the increased level of the
mdr-J gene in certain cancers after chemotherapy, suggesting
a correlation of the expression of the mdr-J gene with
acquired drug resistance.
To find a way to overcome multidrug resistance (MDR), a
combination chemotherapy of anticancer agents and other
agents which may block the drug efflux in MDR cells has
been tested on drug-resistant tumour cells (Tsuruo et al.,
1981; Yamaguchi et al., 1986; Nakagawa et al., 1986; Shir-
aishi et al., 1987). Most of the second agents that can reverse
MDR inhibit the photoaffinity labeling of gpl70 by azido-
pine or a vindesine analog (Cornwell et al., 1986; Safa &
Felsted, 1987; Akiyama et al., 1988); and a polyprenoid with
potent MDR-reversing activity binds specifically to the gpl70
(Akiyama et al., 1989). One can further anticipate that potent
MDR-reversing agents with few side effects and low calcium
channel blocking activity may be useful second agents
in practical cancer chemotherapy. From this standpoint, di-
hydropyridine derivatives with few side effects have been
screened to see if they could overcome MDR. Some dihyd-
ropyridines demonstrated low calcium channel blocking act-
ivity, but potent MDR-reversing activity in vivo (Shinoda et
al., 1989) as well as in vitro (Kamiwatari et al., 1989;
Yoshinari et al., 1989). In our laboratory, among the many
dihydropyridines tested, lipophilic 1,4-dihydropyridines were
found to effectively overcome MDR in vitro (Nogae et al.,
1989). We had further screened 57 newly synthesised 1,4-
dihydropyridine derivatives for their ability to overcome
vincristine (VCR)-resistance in mice with P388 leukaemia
resistant to VCR (P388/VCR) (Kiue et al., 1990a). Represen-
tative 1,4-dihydropyridine derivatives, NK-250 and NK252,
which have low calcium channel blocking activity and very
high affinity for gpl70, could potentiate the antitumour
activity of VCR in mice inoculated i.p. with drug-resistant
tumour cells (Kiue et al., 1990a). In our most recent study,
the p.o. administration of NK-250 and NK-252 was shown
to potentiate the antitumour activity of MDR-related anti-
cancer drugs in mice with drug-sensitive and drug-resistant
tumour cells (Kiue et al., 1990b). In this study, we examined
whether (1) NK-compounds could potentiate the action of
another antitumour agent, etoposide, a semisynthetic deriva-
tive of epipodophyllotoxin, and (2) the effect of NK-com-
pounds on the anticancer activity of etoposide when the
tumour cells and antitumour drugs were administered by
various routes.
Materials and methods
Drugs
Etoposide formulated for clinical use was purchased from
Nippon Kayaku Co. Ltd. (Tokyo, Japan) and was dissolved
in sterilised physiological saline. NK-250 and NK-252 were
synthesised in Omiya Research Laboratory, Nikken Chemi-
cals Co. Ltd. (Saitama, Japan). The chemical structures of
NK-250 and NK-252 are shown in Figure 1. NK-compounds
were suspended in sterilised 0.5% carboxymethyl cellulose
sodium salt containing 0.1% Tween 80 as vehicle.
Animals
Six- to 8-week-old male BALB/c x DBA/2 F1 (hereafter
called CD2F,) mice weighing 22 to 26 g were obtained from
Charles River Japan, Inc. (Kanagawa, Japan). Animals were
given food and tap water ad libitum and kept in a room
conditioned at 22-24°C, 50-60% relative humidity, with 12
fresh air changes per hour.
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Cellgrowth inhibition assay in vitro
Cells from P388/S or resistant subline, P388/VCR, were
harvested from tumour-bearing mice 6 to 7 days after trans-
plantation and were suspended in RPMI-1640 medium with
antitumour agents and/or NK-compounds, seeded at a final
cell density of 5 x 104 cellsml', and incubated in a CO2
incubator at 37°C for 4 days in the absence or presence of
etoposide (Yamaguchi et al., 1986). After culture, 4 ml of
0.25% trypsin-calcium, magnesium-free Ringer buffer solu-
tion was added to 1 ml of cell suspension and incubated for
5 min at 37°C. The number of cells was counted with a
model of ZBI Coulter counter.
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Figure 1 Chemical structures of 1,4-dihydropyridine derivatives:
NK-250 a and NK-252 b.
Cell lines and cell culture
Mouse leukaemia P388 cells sensitive to antitumour drugs,
P388/S, and the subline P388/VCR, resistant to VCR were
kindly supplied by Dr M. Inaba, Japanese Foundation for
Cancer Research (Tokyo, Japan). The passage of each cell
line was made at weekly intervals by i.p. inoculation into
CD2F, mice. Cells from P388/S or resistant subline, P388/
VCR, were grown in suspension in RPMI-1640 medium
(Grand Island Biological Co., Grand Island, NY) supp-
lemented with 10% foetal calf serum (Flow Laboratories,
Inc., Rockville, MD) in the presence of 1Oft M 2-hydroxy-
ethyldisulfide (Aldrich Chemical Co. Inc., Milwaukee, WI)
and 1001g ml1l kanamycin.
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Figure 2 Effects of NK-250 a and NK-252 b on cytotoxic action
of etoposide in P388/S and P388/VCR cells in culture. Exponen-
tially growing P388/S (0, A, 0) and P388/VCR (0, A, *)
cells were seeded and exposed to various doses of etoposide in the
absence (0, 0) or in the presence of 5 lgml- (A, A) and
10 fxg ml-' (0, *) of NK-250 and NK-252. The cells were
further incubated for 4 days and viable cells were scored. Each
value is the average of duplicate dishes within the variation of
less than 10%. The cell growth (% of control) was presented by
normalising cell numbers under various conditions to those in
P388/S or P388/VCR in the absence of any drug.
Evaluation ofantitumour activity
CD2F, mice were inoculated with P388/S or P388/VCR cells
on day 0, either by the i.p. route with 0.2ml of diluted
ascites fluid containing 106 cells (Kiue et al., 1990a) or by the
i.v. route with 0.2 ml of diluted ascites fluid containing lOs
cells. Antitumour agents were given either i.p. once daily
during the initial 5-day period of i.v. once a day on day 1, 3
and 5. NK-250 was given orally (p.o.) once daily during the
first 5 days. Survival of mice was observed during the experi-
mental period of 60 days. Antitumour activity was evaluated
by the mean survival days for each group and also expressed
by the T/C values (%). The data of mean survival days was
analysed by the two-tailed Student's t-test and the two-tailed
Cochran's t-test if the difference of distribution between the
two groups was significant (P<0.05) by the F test.
Results
Potentiation ofetoposide by NK-250 or NK-252 on P388/S
and P388/VCR cells in culture
We examined whether two 1,4-dihydropyridine analogs could
potentiate the cytocidal action of etoposide against mouse
leukaemia P388/S cells and their VCR-resistant P388/VCR
cells. Sensitivity of P388/VCR cells to etoposide was com-
pared with that of the parental counterpart P388/S cells by
assaying growth inhibition in vitro. When P388/S cells were
required for 50% growth inhibition exposed to etoposide
during a 48 h period, the dose of etoposide for P388/S was
about 46 ng ml1', while that for P388/VCR was about
240 ng ml-': P388/VCR was thus 5.2-times more resistant to
Table I Antitumour activity ofNK-250 and NK-252 on P388/S- and
P388/VCR-bearing mice.a
Dose Survival time'
TIC
Cells Drugs (mgkg-') (range) (%)
P388/S
Control 0 8.3 (7-10) 100
NK-250 100 8.8 (8-12) 106
300 9.0 (8-10) 108
1000 9.5 (9-10) 114*C
NK-252 100 8.6 (7-10) 104
300 8.5 (8-9) 102
1000 8.5 (8-9) 102
P388/VCR
Control 0 10.0 (9-11) 100
NK-250 100 9.8 (8-11) 98
300 9.3 (8-10) 93
1000 12.0 (11-14) 120**
NK-252 100 9.5 (6-11) 95
300 9.5 (7-10) 95
1000 10.2 (10-11) 102
aMale CD2F1 mice were inoculated i.p. with 106 cells ofP388/S and
P388/VCR cell line on day 0. Each groupconsisted ofsixmice. NK-250
and NK-252 weregiven p.o. dailyfrom day I to 5. bMean survival days
and the range of survival days. cSignificantly different from the
respective control group by Student's and Cochran's t-test; *P <0.05,
**P<0.01.
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Table II Effect ofNK-250 on antitumour activity ofetoposide on drug-sensitive P388/S-bearing micea
Etoposide: IP adninistrationb Etoposide: IVadministrationc
IP inoculationd IV inoculation IP inoculation IV inoculation
Etoposide NK-250 Survival time TIC survivors Survival time TIC survivors Survival time TIC survivors Survival time TIC survivors
(mgkg-') (mgkg-') (Range) (%) (Range) (%) (Range) (%) (Range) (%)
0 0 8.4 (8-9)e 100 8.3 (8-9) 100 8.9 (6-12) 100 9.6 (9-11) 100
0.3 0 13.4 (12-15) 160 9.0 (9) 108
0.3 300 18.4 (17-20) 219***g 14.5 (10-19) 175***
1.0 0 15.8 (13-18) 188 10.2 (10-11) 123 9.3 (6-12) 104 10.9 (10-11) 114
1.0 300 23.8 (20-32) 283** 27.8 (21-34) 335*** 16.0 (15-17) 180*** 18.0 (15-19) 188***
3.0 0 20.8 (18-25) 248 13.5 (13-15) 163 11.8 (11-13) 133 12.6 (12-13) 131
3.0 100 39.7 (22-60) 473* 2/6h 36.2 (18-60) 436* 1/6 - _
3.0 200 41.3 (21-60) 492 3/6 48.5 (33-60) 584** 3/6 17.2 (16-18) 193*** 22.5 (19-27) 234***
3.0 300 40.3 (21-60) 480* 2/6 45.3 (9-60) 546* 4/6 21.3 (20-23) 239*** 45.3 (28-60) 472*** 2/6
10.0 0 - - - - 16.7 (14-19) 188 17.3 (16-18) 180
10.0 100 - - - - 23.5 (21-29) 264** 51.3 (33-60) 534** 4/6
10.0 200 - - - - 38.8 (22-60) 436* 2/6 53.8 (23-60) 560** 5/6
10.0 300 - - - - 44.0 (30-60) 494** 2/6 26.0 (8-60) 271 2/6
aMaleCD2F, micewereinoculatedi.p. with 106cells ori.v. with 105cellsofP388/Scellline onday0. Thecontrolgroupconsisted of13-19mice, the
etoposide alone group consisted ofsix or 12 mice and the group treated withetoposide and NK-250 consisted of5-6 mice. NK-250 wasgiven p.o.
daily fromday I to 5. bEtoposide wasgiven i.p. dailyfromday I to 5.cEtoposide wasgiven i.v. onday 1, 3 and 5.'Inoculation ofP388/Scells. eMean
survival days and the rangeofsurvivaldays. Thesurvival time formicesurviving more than60days wastaken as60days. '-; not tested. gSignificantly
different from the respective result with the same dose of the etoposide alone group by Student's and Cochran's t-test; *P<0.05; **P<0.01; ***p<0.001. hThe number of mice surviving 60 days/the number of mice treated.
etoposide than P388/S (Figure 2). The combination ofetopo-
side with NK-250 or NK-252 almost completely overcame
the cross-resistance to etoposide of P388/VCR. Both NK-
compounds also potentiated the cytocidal activity of etopo-
side in drug-sensitive P388/S cells. NK-250 and NK-252
could thus potentiate the cytotoxic actions of etoposide
against both P388/S and P388/VCR cells in culture.
Antitumour activity ofNK-250 or NK-252 alone on P388/S-
and P388/VCR-mice
To examine whether NK-250 and NK-252 could potentiate
antitumour activity of etoposide against P388/S and P388/
VCR leukaemia-mice, we first demonstrated whether the two
compounds alone showed antitumour activity in vivo. Daily
p.o. administration of NK-250 alone at 1000 mgkg-' from
day 1 to 5 slightly increased the life-span of mice inoculated
i.p. with 106 cells of P388/S and P388/VCR leukaemia (Table
I). By contrast, NK-250 at 100 and 300 mg kg-l had no such
antitumour activity. NK-252 alone had no antitumour effect
in P388/S- and P388/VCR-mice. For the combination study
with NK-250 or NK-252 and etoposide, we therefore used
both NK-compounds at doses to 300 mg kg-'.
Combined effects ofetoposide and NK-250 on P388/S- and
P388/VCR-mice
We examined whether combinations of etoposide and dihy-
dropyridines could potentiate antitumour activity in drug-
sensitive and drug-resistant P388 leukaemia-mice. We first
determined the effect of a combination of NK-250 and
etoposide on drug-sensitive P388/S-mice. Daily i.p. adminis-
tration ofetoposide increased the life-span ofmice inoculated
i.p. with 106 cells of drug-sensitive P388/S leukaemia (Table
II). The i.p. regimen of etoposide likewise increased the
life-span of mice inoculated i.v. with 105 cells of P388/S
leukaemia. No mice survived longer than 60 days at any dose
of etoposide alone. The combination chemotherapy of etopo-
side administered i.p. with NK-250 administered p.o.
significantly increased the life-span of mice inoculated i.p. or
i.v. with P388/S cells as compared with the corresponding
therapeutic effects of etoposide alone. The combination treat-
ment of i.p. etoposide with p.o. administration of NK-250
resulted in the survival of mice for 60 days. Figure 3a shows
an example of such a therapeutic experiment with P388/S-
mice inoculated i.p. when NK-250 was administered by the
p.o. route and etoposide by the i.p. route. In comparison
with the effects ofetoposide alone, combination with NK-250
significantly extended the life-span of mice with drug-
sensitive leukaemia.
The i.v. administration of etoposide on days 1, 3 and 5
increased the life-span of mice inoculated i.p. or i.v. with
P388/S cells in a dose-dependent manner (Table II). At the
same dose of etoposide, the antitumour activity obtained by
i.v. administration was lower than that by i.p. route in both
groups of mice inoculated i.p. and i.v. with P388/S, although
the frequency of etoposide administration was different for
the two routes, that is, three times for i.v. and five times for
i.p. administration. Combination of both etoposide and NK-
250 by i.v. administration significantly increased the life-span
of mice inoculated i.p. or i.v. with P388/S cells as compared
with the corresponding therapeutic effects of etoposide alone.
Survival for over 60 days was observed when etoposide was
given i.v. with NK-250 to mice inoculated i.p. or i.v. with
P388/S.
We then examined the antitumour effects of a combination
of NK-250 and etoposide on drug-resistant P388/VCR-mice.
Etoposide alone administered i.p. increased in a dose-depen-
dent manner the life-span of mice inoculated i.p. with the
drug-resistant P388/VCR leukaemia (Table III). However,
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Figure 3 Effects of NK-250 on antitumour activity of etoposide
in P388/S A and P388/VCR B-bearing mice. Male CD2F, mice
were inoculated i.p. with 106 cells of P388/S or P388/VCR cells
on day 0. NK-250 was given p.o. and etoposide was given i.p.
daily from day I to 5. Curves a: control; b: etoposide (I mg
kg-'); c: etoposide (3mgkg-'); d: etoposide (I mgkg-') plus
NK-250 (300mgkg-'), significantly (P< 0.01) different from the
curve b in a and P<0.001 from the curve b in b; e: etoposide
(3mgkg-') plus NK-250 (200mgkg-'), significantly (P<0.05)
different from the curve c in b. Each group consisted of six to 12
mice.
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Table III Effect of NK-250 on antitumour activity ofetoposide on VCR-resistant P388/VCR-bearing micea
Etoposide: IP administrationb Etoposide: IV adninistrationc
IP inoculationd IV inoculation IP inoculation IV inoculation
Etoposide NK-250 Survival time TIC survivors Survival time TIC survivors Survival time TIC survivors Survival time TIC survivors
(mgkg-') (mgkg-') (Range) (%) (Range) (%) (Range) (%) (Range) (%)
0 0 9.3 (9-10)' 100 9.4 (8-14) 100 9.9 (7-11) 100 9.8 (9-11) 100
0.3 0 12.2 (11-13) 131 9.2 (9-10) 98
0.3 300 15.7 (14-17) 169***9 11.5 (11-14) 122** -
1.0 0 12.7 (11-14) 137 9.5 (9-11) 101 10.5 (9-14) 106 10.2 (10-11) 104
1.0 300 23.3 (18-27) 251** 16.0 (14-18) 170*** 15.3 (14-18) 155*** 15.2 (14-16) 155***
3.0 0 15.2 (14-16) 163 11.7 (10-20) 124 10.8 (9-12) 109 10.3 (10-11) 105
3.0 100 20.7 (17-23) 223*** 15.8 (14-17) 168 - - - -
3.0 200 34.2 (16-60) 367* 1/6h 23.3 (18-34) 248** 15.7 (14-18) 159*** 17.2 (16-20) 176***
3.0 300 28.2 (8-60) 303 1/6 25.2 (7-46) 268 16.8 (12-20) 170** 19.8 (17-23) 202***
aMaleCD2F, micewereinoculated i.p.with 106cellsori.v. withI05cellsofP388/VCRcelllineonday0.Thecontrolgroupconsistedof11-17mice,
theetoposidealone groupconsisted ofsix or 12miceandthe group treatedwithetoposide and NK-250consisted ofsixmice. NK-250wasgivenp.o.
daily from day 1 to 5. bEtoposide was given i.p. daily from day 1 to 5. cEtoposide was given i.v. on day 1, 3 and 5. dInoculation ofP388/VCR cells.
eMean survival days and the range ofsurvival days. The survival time for mice surviving more than 60 days was taken as 60 days. f-; not tested.
gSignificantly different from the respective result with the same dose of the etoposide alone group by Student's and Cochran's t-test; *P<0.05;
**P<0.01; ***P<0.001. hThe number of mice surviving 60 days/the number ofmice treated.
the same doses ofetoposide alone given i.p. failed to increase
the life-span of mice inoculated i.v. with P388/VCR leu-
kaemia. The combination of etoposide and NK-250 signifi-
cantly increased the life-span of mice inoculated i.p. or i.v.
with P388/VCR cells as compared with the corresponding
therapeutic effects of etoposide alone. In mice inoculated i.p.
with P388/VCR, the combination therapy of i.p. etoposide
with NK-250 resulted in survival of more than 60 days.
Figure 3b shows an example of therapeutic experiment with
P388/VCR-mice inoculated i.p. when NK-250 is administered
p.o. and etoposide i.p. Administration of etoposide alone
extended the survival time, but the therapeutic effect on mice
with P388/VCR was less than that on those with P388/S
(Figure 3A and B).
On the other hand, etoposide alone administered by the
i.v. route could not significantly increase the life-span of mice
inoculated i.p. or i.v. with drug-resistant P388/VCR leu-
kaemia (Table III). Given the same dose of etoposide, the
antitumour activity obtained by i.v. administration was lower
than that achieved by i.p. route in P388/VCR mice, although
there was some difference in frequency of administration for
the two routes. When NK-250 was given together with i.v.
etoposide, the life-span of mice inoculated i.p. or i.v. with
P388/VCR cells was significantly increased.
Table IV Effect of NK-252
P388/VCR-bearing micea
Combined effects ofetoposide and NK-252 on P388/S- and
P388/VCR-mice
We examined the antitumour effects of the combination of
etoposide and another dihydropyridine derivative, NK-252,
against drug-sensitive and drug-resistant leukaemia-bearing
mice. The combination therapy of etoposide with NK-252
administered p.o. significantly increased the life-span of mice
inoculated i.p. with P388/S compared with the corresponding
therapeutic effects with etoposide alone, but the prolonging
effect was less than with NK-250 (Table IV). When etoposide
was combined with NK-252, some mice survived longer than
60 days in the P388/S-mice. On the other hand, combination
therapy with etoposide and NK-252 significantly increased
the life-span of mice inoculated i.p. with P388/VCR com-
pared with the corresponding survival time with etoposide
alone, but the prolonging effect was less than with NK-250.
Discussion
Therapeutic experiments with animal models bearing drug-
sensitive and drug-resistant tumours are often employed to
determine the effectiveness of drug-resistance reversal agents.
on antitumour activity of etoposide on P388/S- and
Etoposide NK-252 Survival time TIC
Cells (mgkg-') (mgkg-') (Range) (%) Survivors
P388/S
0 0 8.4 (8_9)b 100
0.3 0 13.4 (12-15) 160
0.3 300 15.0 (12-17) 179
1.0 0 15.8 (13-18) 188
1.0 300 20.2 (15-27) 240
3.0 0 20.8 (18-25) 248
3.0 200 31.3 (22-60) 373 1/6'
3.0 300 39.7 (23-60) 473*d 2/6C
P388/VCR
0 0 9.3 (9-10) 100
0.3 0 12.2 (11-13) 131
0.3 300 12.8 (10-14) 138
1.0 0 12.7 (11-14) 137
1.0 300 15.3 (14-17) 165**
3.0 0 15.2 (14-16) 163
3.0 200 17.7 (15-19) 190**
3.0 300 19.8 (17-24) 213**
aMaleCD2F, micewere inoculated i.p. with 106cellsofP388/S and P388/VCRcell line
onday 0. Thecontrol groupconsisted of11-13 mice, theetoposide alonegroupconsisted
ofsix to 12 mice and the group treated with etoposide and NK-252 consisted ofsix mice.
NK-252 weregivenp.o. dailyfromday I to 5. Etoposidewasgiveni.p. dailyfromday I to
5. bMean survival days and the rangeofsurvival days; Thesurvival time foreach survival
mouse was calculated at 60 days. cThe number ofmice surviving 60 days/the number of
mice treated. dSignificantly different from the respective result with the same dose ofthe
etoposide alone group by Student's and Cochran's t-test; *P<0.05, **P<0.01,
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Most experiments have been performed using the same route
for both tumour inoculation and administration of chemo-
therapeutic agents, for example, the i.p. route. Various routes
for tumour inoculation and administration of drugs should
be considered for establishment of experimental therapeutic
models. In our present study, we demonstrated that NK-250
and NK-252 administered p.o. in combination with etoposide
administered i.p. or i.v. significantly increased the life-span in
both groups of mice inoculated i.p. and i.v. with P388/S
(Table II and IV). The antitumour activity by etoposide
alone was greatly reduced when the inoculation route for
P388/S cells was changed from i.p. to i.v. (Table II). In these
series of experiments, no mice inoculated i.p. or i.v. with
P388/S survived longer than 60 days when treated using
etoposide alone administered i.p. or i.v. In the combination
therapy by etoposide (i.p. and i.v.) combined with NK-250 or
NK-252 (p.o.), some mice survived longer than 60 days
irrespective of the inoculation routes of P388/S. NK-250 and
NK-252 thus appear to potentiate the antitumour activity of
etoposide. On the other hand, we also demonstrated that
combination with NK-250 or NK-252 effectively potentiated
etoposide against drug-resistant tumour bearing mice (Table
III and IV). The combination with NK-250 restored the
antitumour activity of etoposide in P388/VCR-mice under
various administration routes of tumour inoculation and
etoposide administration.
In this study, we selected NK-250 and NK-252 from 57
NK-compounds as the most favourable compounds to re-
verse MDR. P388/VCR leukaemia cells are shown to have
increased the expression of gpl70 (Kiue et al., 1990b). Con-
sistent with many other MDR-reversal agents that show high
affinity to gpl70 (Cornwell et al., 1986; Safa & Felsted, 1987;
Akiyama et al., 1988 and 1989), NK-250 and NK252 also
show very high affinity to the gpl70 (Kiue et al., 1990a and
1990b). Kamiwatari et al. (1989) and Yoshinari et al. (1989)
have reported that other dihydropyridine derivatives reversed
MDR almost completely in MDR cells in culture, and
effective dihydropyridines showed very high affinity to gpl7O.
A relevant paper by Shinoda et al. (1989) reported that
combination treatment ofVCR administered i.p. VCR with a
1,4-dihydropyridine derivative, AHC-52, administered i.p. in
mice inoculated i.p. with drug-sensitive P388/S leukaemia
resulted in survival of mice for longer than 60 days. The
chemical structures of these dihydropyridine derivatives,
however, are very different from those of NK-compounds.
MDR cells are often cross-resistant to etoposide and its
related epipodophyllotoxin or teniposide, while the resis-
tance levels to etoposide and teniposide are relatively low in
comparison with that to anthracyclines or Vinca alkaloids
(Beck, 1987; Danks et al., 1987). Gpl70 is apparently ex-
pressed in P388/VCR cells, but not in P388/S cells (Kiue et
al., 1990b). Mice with P388/VCR leukaemia are about 3-
times more resistant to the etoposide treatment than mice
with P388/S leukaemia (see Figure 3), suggesting that the
selected drug-resistance model in our present study is one
with a very low degree of resistance. Combination with NK-
250 or NK-252 potentiates the antitumour activity of etopo-
side in both the drug-sensitive P388/S and drug-resistant
P388/VCR mice. Etoposide-resistance in tumour cells might
be partly associated with decreased drug accumulation, pre-
sumably by gp170-mediated enhanced drug efflux, a process
shared by several anticancer agents including Vinca alkaloids,
anthracyclines and actinomycin-D. Yalowich and his col-
leagues (1984 and 1985a) have reported that verapamil, a
potent MDR-reversing agent, potentiates etoposide as well as
VCR and other anticancer agents in drug-sensitive leukaemia
cells in culture. As a plausible mechanism for the potentia-
tion of etoposide, they have demonstrated verapamil-induced
augmentation of etoposide accumulation in the leukaemia
cells in culture (Yalowich & Ross, 1985b). Slater et al. (1986)
have also reported a relevant paper that verapamil can
potentiate etoposide against drug-sensitive and drug-resistant
leukaemia in vitro as well as in vivo. It remains unknown
what mechanisms may be involved in the potentiation of
etoposide by verapamil. Our recent study also demonstrated
that intracellular accumulation of [3H]etoposide was en-
hanced by NK-250 or NK-252 in both drug-sensitive and
their MDR counterpart cell lines in culture (Watanabe et al.,
1990), but neither NK-compounds inhibited the efflux of
etoposide (unpublished data). Inhibition of gp170-mediated
drug efflux thus appears to be only partially, if at all involved
in NK-250 or NK-252-induced potentiation of etoposide
against drug-sensitive tumour cells (Watanabe et al., 1990).
The increased bio-availability of etoposide by dihy-
dropyridine derivative might be mainly due to enhanced
transport of etoposide in tumour cells. Although the exact
mechanims for the dihydropyridine-induced potentiation of
etoposide remain unclear, combination therapy of etoposide
with dihydropyridines such as NK-250 or NK-252 should be
further evaluated.
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